Wilson'S Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
**Disease Name**: Wilson's Disease (WD)
**Classification**: Genetic Metabolic Disorder / Neurodegenerative
**Inheritance**: Autosomal Recessive
**Gene**: [ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- (chromosome 13q14.3)
**OMIM**: 277900
**Prevalence**: 1 in 30,000 to 1 in 100,000
**Onset**: Childhood to adulthood (typically ages 5-35)
Wilson's Disease is a rare autosomal recessive genetic disorder characterized by excessive accumulation of [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- in the body, particularly in the liver, [brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and cornea. The disease results from mutations in the [entities/atp7b-gene|[ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- gene, which encodes a [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---transporting ATPase protein essential for [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- homeostasis[1]. Without appropriate treatment, progressive [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- accumulation leads to severe hepatic and neurological damage, and can be fatal.
The condition was first described by Dr. Samuel Alexander Kinnier Wilson in 1912 in his landmark paper on progressive lenticular degeneration[2]. Wilson's Disease represents one of the few treatable neurodegenerative disorders, making early diagnosis critical for favorable outcomes.
¶ Genetics and Pathophysiology
Wilson's Disease is caused by mutations in the [entities/atp7b-gene|[ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- gene located on chromosome 13q14.3[3]. This gene encodes the [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---transporting ATPase ([ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX--), a protein primarily expressed in hepatocytes that plays a central role in [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- excretion into bile and incorporation into ceruloplasmin.
Over 700 pathogenic mutations in [ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- have been identified, with varying prevalence across populations. The most common mutations include:
- H1069Q (histidine to glutamine at position 1069): Most common in European and North American populations (40-60% of alleles)
- R778L (arginine to leucine): Common in East Asian populations
- Variable mutations in Mediterranean populations
Individuals must inherit two mutated alleles (one from each parent) to develop the disease. Heterozygotes (carriers) typically remain asymptomatic.
Under normal conditions, dietary [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- is absorbed in the intestine and transported to the liver, where:
- [mechanisms/copper-dyshomeostasis|Copper]] is incorporated into ceruloplasmin (a [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---carrying enzyme)
- Excess [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- is excreted into bile for elimination
In Wilson's Disease, the defective [entities/atp7b-gene|[ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- protein fails to:
- Incorporate [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- into ceruloplasmin effectively
- Excrete excess [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- into bile
This leads to:
- Decreased ceruloplasmin-bound [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX--
- Increased "free" toxic [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- in the bloodstream
- Progressive [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- accumulation in liver, [brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, cornea, and other tissues
[mechanisms/copper-dyshomeostasis|Copper]] accumulation in the [brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- produces characteristic neuropathological changes:
- Basal ganglia degeneration: Particularly in the putamen and globus pallidus
- Spongiform changes: Vacuolation and astrogliosis
- [mechanisms/copper-dyshomeostasis|Copper]] deposition: Visible as bronze pigmentation in tissues
- Hepatic cirrhosis: [mechanisms/copper-dyshomeostasis|Copper]]-induced liver damage precedes neurological symptoms
Liver involvement is present in approximately 40-50% of patients and may present as:
- Chronic active hepatitis
- Cirrhosis (micronodular)
- Fulminant hepatic failure
- Asymptomatic hepatomegaly
Neurological symptoms typically develop after hepatic disease, often following a latency of several years.
Neurological symptoms usually appear in the second to third decade of life and include:
- Tremor: Resting, postural, or intention tremor
- Dyskinesias: Chorea, athetosis, dystonia
- Parkinsonism: Bradykinesia, rigidity
- Behavioral changes: Personality changes, irritability
- Depression and anxiety
- Psychosis (less common)
- Cognitive impairment (mild to moderate)
- Dysarthria (slurred speech)
- Dysphagia (difficulty swallowing)
- Ataxia (impaired coordination)
- Seizures (in some cases)
A characteristic ocular finding is the Kayser-Fleischer ring - a brownish-gold ring of [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- deposition in Descemet's membrane of the cornea. Present in approximately 95% of patients with neurological involvement[4], but only 50% of those with isolated hepatic disease.
- Hemolytic anemia: Due to oxidative damage from free [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX--
- Renal dysfunction: Fanconi syndrome or renal tubular acidosis
- Cardiomyopathy (rare)
- Endocrine abnormalities: Hypoparathyroidism, diabetes mellitus
The diagnosis is established based on a combination of clinical, biochemical, and genetic findings:
- Low serum ceruloplasmin (<20 mg/dL) - present in 85-90% of patients
- Elevated 24-hour urinary [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- excretion (>100 μg/24 hours)
- Kayser-Fleischer rings on slit-lamp examination
- Elevated hepatic [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- content (>250 μg/g dry weight) - gold standard
- [entities/atp7b-gene|[ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- gene mutations - confirmatory genetic testing
- Serum ceruloplasmin (low in most cases)
- 24-hour urinary [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- collection
- Liver function tests
- Complete blood count (may show hemolytic anemia)
- Serum [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- (may be normal or elevated)
- MRI [brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: May show T2 hyperintensities in basal ganglia, particularly putamen
- CT [brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: May show ventricular enlargement or basal ganglia calcification
- [entities/atp7b-gene|[ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- gene sequencing
- Useful for confirming diagnosis and identifying carrier status in families
The Revised Wilson's Disease Diagnostic Score (Leipzig score) incorporates clinical, biochemical, and genetic findings:
- Score ≥4: Wilson's Disease diagnosed
- Score 2-3: Diagnosis uncertain, requires further investigation
- Score <2: Wilson's Disease unlikely
Treatment aims to:
- Reduce [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- intake
- Remove excess [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- from the body
- Treat complications
- Monitor for treatment response
Penicillamine (D-penicillamine):
- First-line chelating agent since 1956
- Promotes renal [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- excretion
- Side effects: Bone marrow suppression, nephrotoxicity, neurological worsening (in 10-50%)
Trientine:
- Alternative chelator with fewer side effects
- Preferred over penicillamine in many cases
- Effective in promoting [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- excretion
Zinc salts (zinc acetate, zinc gluconate):
- Block intestinal [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- absorption
- Useful for maintenance therapy or in presymptomatic patients
- Fewer side effects than chelators
- Avoid [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---rich foods (liver, shellfish, nuts, chocolate)
- Use [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---depleted water
Indicated in:
- Fulminant hepatic failure
- Decompensated cirrhosis unresponsive to medical therapy
- Neurological disease unresponsive to chelation (controversial)
- Serum non-ceruloplasmin-bound [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX--
- 24-hour urinary [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- excretion
- Liver function tests
- Neurological examination
With early diagnosis and appropriate treatment:
- Excellent prognosis when treatment begins before significant organ damage
- Neurological symptoms improve in 50-70% of patients
- Liver disease often stabilizes or improves
- Life expectancy approaches normal with lifelong treatment
Without treatment:
- Progressive liver failure
- Severe neurological disability
- Fatal outcome typically within 5-10 years of symptom onset
- Prevalence: 1 in 30,000 to 1 in 100,000 worldwide
- Carrier frequency: Approximately 1 in 90
- Age of onset: 5-35 years (most common in adolescence/young adulthood)
- Equal distribution between males and females
Other conditions causing hepatic or neurological symptoms:
- Chronic hepatitis (viral, autoimmune)
- Other causes of cirrhosis
- Other movement disorders (Huntington's Disease, Parkinson's Disease)
- Other causes of basal ganglia disease
- Menkes disease (X-linked recessive [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- deficiency)
Current research areas include:
- Gene therapy: Viral vector delivery of functional [ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX--
- Novel chelators: More effective and safer [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---binding compounds
- Biomarkers: Improved early detection and treatment monitoring
- Understanding phenotypic variability: Why some patients present primarily with liver disease while others develop neurological symptoms
¶ Biomarker Refinement for Diagnosis and Monitoring
Recent work has strengthened blood-based and serum-based [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- biomarkers for [Wilson's Disease[/diseases/[wilson-disease[/diseases/[wilson-disease[/diseases/[wilson-disease[/diseases/[wilson-disease--TEMP--/diseases)--FIX--, especially exchangeable [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- (CuEXC) and relative exchangeable [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX--
(REC). These assays improve diagnostic discrimination in challenging presentations (including mixed hepatic-neurologic phenotypes) and can help monitor longitudinal response
during chelation or zinc maintenance[9][10][11]. These measurements are increasingly discussed
as
complements to traditional panels (ceruloplasmin, urinary [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX--, and hepatic [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- quantification) rather than simple replacements.
Large cohort analyses indicate that [ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- variant class may affect long-term outcomes, including transplant-free survival in chronic liver-dominant disease. In particular, loss-of-function variant profiles were associated with poorer hepatic outcomes, supporting more proactive surveillance and treatment escalation in higher-risk genotypes[12].
Bis-choline tetrathiomolybdate development has advanced from mechanistic pharmacology into newer clinical datasets showing rapid impact on [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- balance metrics, with ongoing
evaluation of durability, tolerability, and comparative positioning versus established chelators and zinc regimens[13][14].
Advanced MRI studies now provide finer-grained markers of neurologic burden in [Wilson's Disease[/diseases/[wilson-disease[/diseases/[wilson-disease[/diseases/[wilson-disease[/diseases/[wilson-disease--TEMP--/diseases)--FIX--, including quantitative susceptibility and multimodal structural patterns in the
[basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--. These findings connect radiographic abnormalities with motor and cognitive phenotypes, and may improve monitoring in neurologic-predominant disease[15][16][17]. Mechanistically, these imaging signatures align with [Copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- Dyshomeostasis in Neurodegeneration], [Oxidative Stress in
Neurodegeneration], and [neuroinflammation in Neurodegenerative Diseases[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--.
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
The study of Wilson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ferenci P. Pathophysiology and clinical features of Wilson disease. Hepatol Int. 2021;15(1):20-29. DOI:10.1007/s12072-020-10126-4
- Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain. 1912;34(2-3):295-509. [DOI:10.1093/brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--/34.2-3.295
- Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX---transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5(4):327-337. DOI:10.1038/ng1293-327
- Esmaeeli S, Schilsky ML. Wilson Disease. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 11th ed. Elsevier; 2021:1280-1291.
- Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089-2111. DOI:10.1002/hep.22261
- Ala A, Schilsky ML. Wilson disease: pathogenesis, clinical manifestations, and diagnosis. Semin Liver Dis. 2018;38(2):123-132. DOI:10.1055/s-0038-1669941
- Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. DOI:10.1038/s41572-018-0018-3
- Ferenci P, Ca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-142. DOI:10.1034/j.1600-0676.2003.00824.x
- [Gromadzka G, et al. Monitoring of [mechanisms/copper-dyshomeostasis|Copper]] in Wilson Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37296680/)
- [Djebrani-Oussedik N, et al. Relative exchangeable [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX--: A highly specific and sensitive biomarker for Wilson disease diagnosis (2025)(https://pubmed.ncbi.nlm.nih.gov/40980162/)
- [Lorenzen C, et al. Relative Exchangeable [mechanisms/copper-dyshomeostasis|Copper]], Exchangeable [mechanisms/copper-dyshomeostasis|Copper]] and Total [mechanisms/copper-dyshomeostasis|Copper]] in the Diagnosis of Wilson Disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40198317/)
- [Nayagam JS, et al. [ATP7B[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene[/entities/[atp7b-gene--TEMP--/entities)--FIX-- Genotype and Chronic Liver Disease Treatment Outcomes in Wilson Disease (2023)(https://pubmed.ncbi.nlm.nih.gov/36096368/)
- [Kirk FT, et al. Effects of tetrathiomolybdate on [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- metabolism in healthy volunteers and in patients with Wilson disease (2024)(https://pubmed.ncbi.nlm.nih.gov/38081365/)
- [Ala A, et al. Oral bis-choline tetrathiomolybdate rapidly improves [copper[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis[/mechanisms/[copper-dyshomeostasis--TEMP--/mechanisms)--FIX-- balance in patients with Wilson disease (2025)(https://pubmed.ncbi.nlm.nih.gov/40975404/)
- [Shribman S, et al. Neuroimaging correlates of [brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- injury in Wilson's Disease: a multimodal, whole-[brain[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- MRI study (2022)(https://pubmed.ncbi.nlm.nih.gov/34289020/)
- [Su D, et al. Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease: Insights From 7T Susceptibility-Weighted Imaging (2024)(https://pubmed.ncbi.nlm.nih.gov/38830145/)
- [Litwin T, et al. Brain Magnetic Resonance Imaging in Wilson's Disease-Significance and Practical Aspects-A Narrative Review (2024)(https://pubmed.ncbi.nlm.nih.gov/39061467/)